Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Halozyme Therapeutics (HALO) , which belongs to the Zacks Medical - Biomedical and Genetics industry.This biopharmaceutical company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 21.02%.For the most recent quarter, Halozyme Therapeutics was expected ...